Cann Pharmaceutical Australia was the first Australian company to obtain a joint venture with a licensed medicinal cannabis company in Israel - Cann Pharmaceutical Ltd of Israel.
In Australia, our management, board of directors and advisors consist of proven business, academic and medical leaders with extensive history of achievement in the medicinal cannabis sector, clinical research and biotechnology.
Collectively, our breadth of experience ranges from advanced agribusiness technology, biotechnology, healthcare and the pharmaceutical sectors, plus proven entrepreneurial and business development in Australia, New Zealand, and Israel.
Dr Braden McGrath
Shahar bar David
Company Secretary - Automic Group
Braden is CEO responsible for leadership of the business and developing strategies for penetrating new markets. Formerly, Braden was CEO of a medical device startup, and CTO of multi-national defense and security company.
Rachel is is responsible for leading and managing our clinical research trials, including developing research agendas and pipeline, while maintaining regulatory and compliance requirements. Rachel holds an Honours degree in Clinical Neuroscience.
Chief Argonomist for better Holdings of Israel and is responsible for training Australia’s farm management staff. Shahar has over 14 years of experience plant cultivation management. He holds a MS in Argonomy from the Hebrew University and an MBA from Ben Gurion University.